Biodesix (BDSX) Capital Expenditures (2019 - 2026)

Biodesix has reported Capital Expenditures for 8 years, with the latest figure at $81000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 9.46% year-over-year to $81000.0; the trailing twelve-month figure through Mar 2026 stood at $266000.0 (down 91.34% YoY), and the FY2025 full-year result was $259000.0, down 91.98% from the prior year.
• Capital Expenditures for Q1 2026 stood at $81000.0, down from $86000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $7.7 million in Q1 2023, with the low at $48000.0 in Q3 2025.
• Historically, Capital Expenditures has averaged $1.8 million across 5 years, with a median of $329000.0 in 2022.
• Annual changes were most pronounced in 2023 — Capital Expenditures surged 2829.77% — and 2025, when it plunged 97.35%.
• Biodesix's Capital Expenditures stood at $1.9 million in 2022, then soared by 54.61% to $3.0 million in 2023, then tumbled by 71.88% to $839000.0 in 2024, then slumped by 89.75% to $86000.0 in 2025, then slipped by 5.81% to $81000.0 in 2026.
• The last three Capital Expenditures figures came in at $81000.0 (Q1 2026), $86000.0 (Q4 2025), and $48000.0 (Q3 2025), per Business Quant data.